Global Idiopathic Hypersomnia Treatment Market Research Report 2023
Idiopathic hypersomnia (IH) is a rare sleep disorder marked by an over sleeping duration time during the day even after a longer sleeping hours of night sleep. People with idiopathic hypersomnia sleep normal or for long hours each night but still feel excessively sleepy during the day. Idiopathic hypersomnia is a type of hypersomnia and symptoms include chronic excessive daytime sleepiness (EDS), non-refreshing daytime napping, sleep drunkenness after nighttime sleep, naps, and others. Idiopathic hypersomnia is a nervous system disease, whose cause is not known. There is no single drug available that is approved by the U.S. FDA for this disease, but medicines such as dextroamphetamine that are approved for narcolepsy, one of the types of hypersomnia can be used for idiopathic hypersomnia off-label.
According to QYResearch’s new survey, global Idiopathic Hypersomnia Treatment market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Idiopathic Hypersomnia Treatment market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Idiopathic Hypersomnia Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
According to QYResearch’s new survey, global Idiopathic Hypersomnia Treatment market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Idiopathic Hypersomnia Treatment market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Idiopathic Hypersomnia Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Takeda Pharmaceutical
- Teva Pharmaceutical Industries
- Jazz Pharmaceuticals
- BIOPROJET
- Avadel Pharmaceuticals
- GlaxoSmithKline
- Pfizer
- Theranexus
- Fisher and Paykel Healthcare
- Drive DeVilbiss Healthcare
- Merck
- Stimulant Medications
- Non-Stimulant Wake-Promoting Medications
- Sodium Oxybate
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Idiopathic Hypersomnia Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Stimulant Medications
1.2.3 Non-Stimulant Wake-Promoting Medications
1.2.4 Sodium Oxybate
1.3 Market by Application
1.3.1 Global Idiopathic Hypersomnia Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Idiopathic Hypersomnia Treatment Market Perspective (2018-2029)
2.2 Idiopathic Hypersomnia Treatment Growth Trends by Region
2.2.1 Global Idiopathic Hypersomnia Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Idiopathic Hypersomnia Treatment Historic Market Size by Region (2018-2023)
2.2.3 Idiopathic Hypersomnia Treatment Forecasted Market Size by Region (2024-2029)
2.3 Idiopathic Hypersomnia Treatment Market Dynamics
2.3.1 Idiopathic Hypersomnia Treatment Industry Trends
2.3.2 Idiopathic Hypersomnia Treatment Market Drivers
2.3.3 Idiopathic Hypersomnia Treatment Market Challenges
2.3.4 Idiopathic Hypersomnia Treatment Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Idiopathic Hypersomnia Treatment Players by Revenue
3.1.1 Global Top Idiopathic Hypersomnia Treatment Players by Revenue (2018-2023)
3.1.2 Global Idiopathic Hypersomnia Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Idiopathic Hypersomnia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Idiopathic Hypersomnia Treatment Revenue
3.4 Global Idiopathic Hypersomnia Treatment Market Concentration Ratio
3.4.1 Global Idiopathic Hypersomnia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Hypersomnia Treatment Revenue in 2022
3.5 Idiopathic Hypersomnia Treatment Key Players Head office and Area Served
3.6 Key Players Idiopathic Hypersomnia Treatment Product Solution and Service
3.7 Date of Enter into Idiopathic Hypersomnia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 IDIOPATHIC HYPERSOMNIA TREATMENT BREAKDOWN DATA BY TYPE
4.1 Global Idiopathic Hypersomnia Treatment Historic Market Size by Type (2018-2023)
4.2 Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Type (2024-2029)
5 IDIOPATHIC HYPERSOMNIA TREATMENT BREAKDOWN DATA BY APPLICATION
5.1 Global Idiopathic Hypersomnia Treatment Historic Market Size by Application (2018-2023)
5.2 Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Idiopathic Hypersomnia Treatment Market Size (2018-2029)
6.2 North America Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023)
6.4 North America Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Idiopathic Hypersomnia Treatment Market Size (2018-2029)
7.2 Europe Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023)
7.4 Europe Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size (2018-2029)
8.2 Asia-Pacific Idiopathic Hypersomnia Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Idiopathic Hypersomnia Treatment Market Size (2018-2029)
9.2 Latin America Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023)
9.4 Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size (2018-2029)
10.2 Middle East & Africa Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Takeda Pharmaceutical
11.1.1 Takeda Pharmaceutical Company Detail
11.1.2 Takeda Pharmaceutical Business Overview
11.1.3 Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Introduction
11.1.4 Takeda Pharmaceutical Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.1.5 Takeda Pharmaceutical Recent Development
11.2 Teva Pharmaceutical Industries
11.2.1 Teva Pharmaceutical Industries Company Detail
11.2.2 Teva Pharmaceutical Industries Business Overview
11.2.3 Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Introduction
11.2.4 Teva Pharmaceutical Industries Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.2.5 Teva Pharmaceutical Industries Recent Development
11.3 Jazz Pharmaceuticals
11.3.1 Jazz Pharmaceuticals Company Detail
11.3.2 Jazz Pharmaceuticals Business Overview
11.3.3 Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Introduction
11.3.4 Jazz Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.3.5 Jazz Pharmaceuticals Recent Development
11.4 BIOPROJET
11.4.1 BIOPROJET Company Detail
11.4.2 BIOPROJET Business Overview
11.4.3 BIOPROJET Idiopathic Hypersomnia Treatment Introduction
11.4.4 BIOPROJET Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.4.5 BIOPROJET Recent Development
11.5 Avadel Pharmaceuticals
11.5.1 Avadel Pharmaceuticals Company Detail
11.5.2 Avadel Pharmaceuticals Business Overview
11.5.3 Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Introduction
11.5.4 Avadel Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.5.5 Avadel Pharmaceuticals Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Detail
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Idiopathic Hypersomnia Treatment Introduction
11.6.4 GlaxoSmithKline Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.6.5 GlaxoSmithKline Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Idiopathic Hypersomnia Treatment Introduction
11.7.4 Pfizer Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Theranexus
11.8.1 Theranexus Company Detail
11.8.2 Theranexus Business Overview
11.8.3 Theranexus Idiopathic Hypersomnia Treatment Introduction
11.8.4 Theranexus Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.8.5 Theranexus Recent Development
11.9 Fisher and Paykel Healthcare
11.9.1 Fisher and Paykel Healthcare Company Detail
11.9.2 Fisher and Paykel Healthcare Business Overview
11.9.3 Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Introduction
11.9.4 Fisher and Paykel Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.9.5 Fisher and Paykel Healthcare Recent Development
11.10 Drive DeVilbiss Healthcare
11.10.1 Drive DeVilbiss Healthcare Company Detail
11.10.2 Drive DeVilbiss Healthcare Business Overview
11.10.3 Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Introduction
11.10.4 Drive DeVilbiss Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.10.5 Drive DeVilbiss Healthcare Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Idiopathic Hypersomnia Treatment Introduction
11.11.4 Merck Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.11.5 Merck Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Idiopathic Hypersomnia Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Stimulant Medications
1.2.3 Non-Stimulant Wake-Promoting Medications
1.2.4 Sodium Oxybate
1.3 Market by Application
1.3.1 Global Idiopathic Hypersomnia Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Idiopathic Hypersomnia Treatment Market Perspective (2018-2029)
2.2 Idiopathic Hypersomnia Treatment Growth Trends by Region
2.2.1 Global Idiopathic Hypersomnia Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Idiopathic Hypersomnia Treatment Historic Market Size by Region (2018-2023)
2.2.3 Idiopathic Hypersomnia Treatment Forecasted Market Size by Region (2024-2029)
2.3 Idiopathic Hypersomnia Treatment Market Dynamics
2.3.1 Idiopathic Hypersomnia Treatment Industry Trends
2.3.2 Idiopathic Hypersomnia Treatment Market Drivers
2.3.3 Idiopathic Hypersomnia Treatment Market Challenges
2.3.4 Idiopathic Hypersomnia Treatment Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Idiopathic Hypersomnia Treatment Players by Revenue
3.1.1 Global Top Idiopathic Hypersomnia Treatment Players by Revenue (2018-2023)
3.1.2 Global Idiopathic Hypersomnia Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Idiopathic Hypersomnia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Idiopathic Hypersomnia Treatment Revenue
3.4 Global Idiopathic Hypersomnia Treatment Market Concentration Ratio
3.4.1 Global Idiopathic Hypersomnia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Hypersomnia Treatment Revenue in 2022
3.5 Idiopathic Hypersomnia Treatment Key Players Head office and Area Served
3.6 Key Players Idiopathic Hypersomnia Treatment Product Solution and Service
3.7 Date of Enter into Idiopathic Hypersomnia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 IDIOPATHIC HYPERSOMNIA TREATMENT BREAKDOWN DATA BY TYPE
4.1 Global Idiopathic Hypersomnia Treatment Historic Market Size by Type (2018-2023)
4.2 Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Type (2024-2029)
5 IDIOPATHIC HYPERSOMNIA TREATMENT BREAKDOWN DATA BY APPLICATION
5.1 Global Idiopathic Hypersomnia Treatment Historic Market Size by Application (2018-2023)
5.2 Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Idiopathic Hypersomnia Treatment Market Size (2018-2029)
6.2 North America Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023)
6.4 North America Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Idiopathic Hypersomnia Treatment Market Size (2018-2029)
7.2 Europe Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023)
7.4 Europe Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size (2018-2029)
8.2 Asia-Pacific Idiopathic Hypersomnia Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Idiopathic Hypersomnia Treatment Market Size (2018-2029)
9.2 Latin America Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023)
9.4 Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size (2018-2029)
10.2 Middle East & Africa Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Takeda Pharmaceutical
11.1.1 Takeda Pharmaceutical Company Detail
11.1.2 Takeda Pharmaceutical Business Overview
11.1.3 Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Introduction
11.1.4 Takeda Pharmaceutical Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.1.5 Takeda Pharmaceutical Recent Development
11.2 Teva Pharmaceutical Industries
11.2.1 Teva Pharmaceutical Industries Company Detail
11.2.2 Teva Pharmaceutical Industries Business Overview
11.2.3 Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Introduction
11.2.4 Teva Pharmaceutical Industries Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.2.5 Teva Pharmaceutical Industries Recent Development
11.3 Jazz Pharmaceuticals
11.3.1 Jazz Pharmaceuticals Company Detail
11.3.2 Jazz Pharmaceuticals Business Overview
11.3.3 Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Introduction
11.3.4 Jazz Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.3.5 Jazz Pharmaceuticals Recent Development
11.4 BIOPROJET
11.4.1 BIOPROJET Company Detail
11.4.2 BIOPROJET Business Overview
11.4.3 BIOPROJET Idiopathic Hypersomnia Treatment Introduction
11.4.4 BIOPROJET Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.4.5 BIOPROJET Recent Development
11.5 Avadel Pharmaceuticals
11.5.1 Avadel Pharmaceuticals Company Detail
11.5.2 Avadel Pharmaceuticals Business Overview
11.5.3 Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Introduction
11.5.4 Avadel Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.5.5 Avadel Pharmaceuticals Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Detail
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Idiopathic Hypersomnia Treatment Introduction
11.6.4 GlaxoSmithKline Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.6.5 GlaxoSmithKline Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Idiopathic Hypersomnia Treatment Introduction
11.7.4 Pfizer Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Theranexus
11.8.1 Theranexus Company Detail
11.8.2 Theranexus Business Overview
11.8.3 Theranexus Idiopathic Hypersomnia Treatment Introduction
11.8.4 Theranexus Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.8.5 Theranexus Recent Development
11.9 Fisher and Paykel Healthcare
11.9.1 Fisher and Paykel Healthcare Company Detail
11.9.2 Fisher and Paykel Healthcare Business Overview
11.9.3 Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Introduction
11.9.4 Fisher and Paykel Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.9.5 Fisher and Paykel Healthcare Recent Development
11.10 Drive DeVilbiss Healthcare
11.10.1 Drive DeVilbiss Healthcare Company Detail
11.10.2 Drive DeVilbiss Healthcare Business Overview
11.10.3 Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Introduction
11.10.4 Drive DeVilbiss Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.10.5 Drive DeVilbiss Healthcare Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Idiopathic Hypersomnia Treatment Introduction
11.11.4 Merck Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
11.11.5 Merck Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Idiopathic Hypersomnia Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Stimulant Medications
Table 3. Key Players of Non-Stimulant Wake-Promoting Medications
Table 4. Key Players of Sodium Oxybate
Table 5. Global Idiopathic Hypersomnia Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Idiopathic Hypersomnia Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Idiopathic Hypersomnia Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Idiopathic Hypersomnia Treatment Market Share by Region (2018-2023)
Table 9. Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Idiopathic Hypersomnia Treatment Market Share by Region (2024-2029)
Table 11. Idiopathic Hypersomnia Treatment Market Trends
Table 12. Idiopathic Hypersomnia Treatment Market Drivers
Table 13. Idiopathic Hypersomnia Treatment Market Challenges
Table 14. Idiopathic Hypersomnia Treatment Market Restraints
Table 15. Global Idiopathic Hypersomnia Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Idiopathic Hypersomnia Treatment Market Share by Players (2018-2023)
Table 17. Global Top Idiopathic Hypersomnia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Hypersomnia Treatment as of 2022)
Table 18. Ranking of Global Top Idiopathic Hypersomnia Treatment Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Idiopathic Hypersomnia Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Idiopathic Hypersomnia Treatment Product Solution and Service
Table 22. Date of Enter into Idiopathic Hypersomnia Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Idiopathic Hypersomnia Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2018-2023)
Table 26. Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2024-2029)
Table 28. Global Idiopathic Hypersomnia Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2018-2023)
Table 30. Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2024-2029)
Table 32. North America Idiopathic Hypersomnia Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 33. North America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 35. Europe Idiopathic Hypersomnia Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. Europe Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 38. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 39. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 41. Latin America Idiopathic Hypersomnia Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 42. Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 44. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 47. Takeda Pharmaceutical Company Detail
Table 48. Takeda Pharmaceutical Business Overview
Table 49. Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Product
Table 50. Takeda Pharmaceutical Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 51. Takeda Pharmaceutical Recent Development
Table 52. Teva Pharmaceutical Industries Company Detail
Table 53. Teva Pharmaceutical Industries Business Overview
Table 54. Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Product
Table 55. Teva Pharmaceutical Industries Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 56. Teva Pharmaceutical Industries Recent Development
Table 57. Jazz Pharmaceuticals Company Detail
Table 58. Jazz Pharmaceuticals Business Overview
Table 59. Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Product
Table 60. Jazz Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 61. Jazz Pharmaceuticals Recent Development
Table 62. BIOPROJET Company Detail
Table 63. BIOPROJET Business Overview
Table 64. BIOPROJET Idiopathic Hypersomnia Treatment Product
Table 65. BIOPROJET Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 66. BIOPROJET Recent Development
Table 67. Avadel Pharmaceuticals Company Detail
Table 68. Avadel Pharmaceuticals Business Overview
Table 69. Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Product
Table 70. Avadel Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 71. Avadel Pharmaceuticals Recent Development
Table 72. GlaxoSmithKline Company Detail
Table 73. GlaxoSmithKline Business Overview
Table 74. GlaxoSmithKline Idiopathic Hypersomnia Treatment Product
Table 75. GlaxoSmithKline Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 76. GlaxoSmithKline Recent Development
Table 77. Pfizer Company Detail
Table 78. Pfizer Business Overview
Table 79. Pfizer Idiopathic Hypersomnia Treatment Product
Table 80. Pfizer Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. Theranexus Company Detail
Table 83. Theranexus Business Overview
Table 84. Theranexus Idiopathic Hypersomnia Treatment Product
Table 85. Theranexus Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 86. Theranexus Recent Development
Table 87. Fisher and Paykel Healthcare Company Detail
Table 88. Fisher and Paykel Healthcare Business Overview
Table 89. Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Product
Table 90. Fisher and Paykel Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 91. Fisher and Paykel Healthcare Recent Development
Table 92. Drive DeVilbiss Healthcare Company Detail
Table 93. Drive DeVilbiss Healthcare Business Overview
Table 94. Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Product
Table 95. Drive DeVilbiss Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 96. Drive DeVilbiss Healthcare Recent Development
Table 97. Merck Company Detail
Table 98. Merck Business Overview
Table 99. Merck Idiopathic Hypersomnia Treatment Product
Table 100. Merck Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 101. Merck Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
Table 1. Global Idiopathic Hypersomnia Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Stimulant Medications
Table 3. Key Players of Non-Stimulant Wake-Promoting Medications
Table 4. Key Players of Sodium Oxybate
Table 5. Global Idiopathic Hypersomnia Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Idiopathic Hypersomnia Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Idiopathic Hypersomnia Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Idiopathic Hypersomnia Treatment Market Share by Region (2018-2023)
Table 9. Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Idiopathic Hypersomnia Treatment Market Share by Region (2024-2029)
Table 11. Idiopathic Hypersomnia Treatment Market Trends
Table 12. Idiopathic Hypersomnia Treatment Market Drivers
Table 13. Idiopathic Hypersomnia Treatment Market Challenges
Table 14. Idiopathic Hypersomnia Treatment Market Restraints
Table 15. Global Idiopathic Hypersomnia Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Idiopathic Hypersomnia Treatment Market Share by Players (2018-2023)
Table 17. Global Top Idiopathic Hypersomnia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Hypersomnia Treatment as of 2022)
Table 18. Ranking of Global Top Idiopathic Hypersomnia Treatment Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Idiopathic Hypersomnia Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Idiopathic Hypersomnia Treatment Product Solution and Service
Table 22. Date of Enter into Idiopathic Hypersomnia Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Idiopathic Hypersomnia Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2018-2023)
Table 26. Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2024-2029)
Table 28. Global Idiopathic Hypersomnia Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2018-2023)
Table 30. Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2024-2029)
Table 32. North America Idiopathic Hypersomnia Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 33. North America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 35. Europe Idiopathic Hypersomnia Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. Europe Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 38. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 39. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 41. Latin America Idiopathic Hypersomnia Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 42. Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 44. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 47. Takeda Pharmaceutical Company Detail
Table 48. Takeda Pharmaceutical Business Overview
Table 49. Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Product
Table 50. Takeda Pharmaceutical Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 51. Takeda Pharmaceutical Recent Development
Table 52. Teva Pharmaceutical Industries Company Detail
Table 53. Teva Pharmaceutical Industries Business Overview
Table 54. Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Product
Table 55. Teva Pharmaceutical Industries Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 56. Teva Pharmaceutical Industries Recent Development
Table 57. Jazz Pharmaceuticals Company Detail
Table 58. Jazz Pharmaceuticals Business Overview
Table 59. Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Product
Table 60. Jazz Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 61. Jazz Pharmaceuticals Recent Development
Table 62. BIOPROJET Company Detail
Table 63. BIOPROJET Business Overview
Table 64. BIOPROJET Idiopathic Hypersomnia Treatment Product
Table 65. BIOPROJET Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 66. BIOPROJET Recent Development
Table 67. Avadel Pharmaceuticals Company Detail
Table 68. Avadel Pharmaceuticals Business Overview
Table 69. Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Product
Table 70. Avadel Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 71. Avadel Pharmaceuticals Recent Development
Table 72. GlaxoSmithKline Company Detail
Table 73. GlaxoSmithKline Business Overview
Table 74. GlaxoSmithKline Idiopathic Hypersomnia Treatment Product
Table 75. GlaxoSmithKline Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 76. GlaxoSmithKline Recent Development
Table 77. Pfizer Company Detail
Table 78. Pfizer Business Overview
Table 79. Pfizer Idiopathic Hypersomnia Treatment Product
Table 80. Pfizer Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. Theranexus Company Detail
Table 83. Theranexus Business Overview
Table 84. Theranexus Idiopathic Hypersomnia Treatment Product
Table 85. Theranexus Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 86. Theranexus Recent Development
Table 87. Fisher and Paykel Healthcare Company Detail
Table 88. Fisher and Paykel Healthcare Business Overview
Table 89. Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Product
Table 90. Fisher and Paykel Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 91. Fisher and Paykel Healthcare Recent Development
Table 92. Drive DeVilbiss Healthcare Company Detail
Table 93. Drive DeVilbiss Healthcare Business Overview
Table 94. Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Product
Table 95. Drive DeVilbiss Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 96. Drive DeVilbiss Healthcare Recent Development
Table 97. Merck Company Detail
Table 98. Merck Business Overview
Table 99. Merck Idiopathic Hypersomnia Treatment Product
Table 100. Merck Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US$ Million)
Table 101. Merck Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Idiopathic Hypersomnia Treatment Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Idiopathic Hypersomnia Treatment Market Share by Type: 2022 VS 2029
Figure 3. Stimulant Medications Features
Figure 4. Non-Stimulant Wake-Promoting Medications Features
Figure 5. Sodium Oxybate Features
Figure 6. Global Idiopathic Hypersomnia Treatment Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Idiopathic Hypersomnia Treatment Market Share by Application: 2022 VS 2029
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. Idiopathic Hypersomnia Treatment Report Years Considered
Figure 12. Global Idiopathic Hypersomnia Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Idiopathic Hypersomnia Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Idiopathic Hypersomnia Treatment Market Share by Region: 2022 VS 2029
Figure 15. Global Idiopathic Hypersomnia Treatment Market Share by Players in 2022
Figure 16. Global Top Idiopathic Hypersomnia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Hypersomnia Treatment as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Idiopathic Hypersomnia Treatment Revenue in 2022
Figure 18. North America Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Idiopathic Hypersomnia Treatment Market Share by Country (2018-2029)
Figure 20. United States Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Idiopathic Hypersomnia Treatment Market Share by Country (2018-2029)
Figure 24. Germany Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Idiopathic Hypersomnia Treatment Market Share by Region (2018-2029)
Figure 32. China Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Idiopathic Hypersomnia Treatment Market Share by Country (2018-2029)
Figure 40. Mexico Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Idiopathic Hypersomnia Treatment Market Share by Country (2018-2029)
Figure 44. Turkey Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Takeda Pharmaceutical Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 47. Teva Pharmaceutical Industries Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 48. Jazz Pharmaceuticals Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 49. BIOPROJET Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 50. Avadel Pharmaceuticals Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 51. GlaxoSmithKline Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 52. Pfizer Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 53. Theranexus Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 54. Fisher and Paykel Healthcare Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 55. Drive DeVilbiss Healthcare Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 56. Merck Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Figure 1. Global Idiopathic Hypersomnia Treatment Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Idiopathic Hypersomnia Treatment Market Share by Type: 2022 VS 2029
Figure 3. Stimulant Medications Features
Figure 4. Non-Stimulant Wake-Promoting Medications Features
Figure 5. Sodium Oxybate Features
Figure 6. Global Idiopathic Hypersomnia Treatment Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Idiopathic Hypersomnia Treatment Market Share by Application: 2022 VS 2029
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. Idiopathic Hypersomnia Treatment Report Years Considered
Figure 12. Global Idiopathic Hypersomnia Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Idiopathic Hypersomnia Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Idiopathic Hypersomnia Treatment Market Share by Region: 2022 VS 2029
Figure 15. Global Idiopathic Hypersomnia Treatment Market Share by Players in 2022
Figure 16. Global Top Idiopathic Hypersomnia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Hypersomnia Treatment as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Idiopathic Hypersomnia Treatment Revenue in 2022
Figure 18. North America Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Idiopathic Hypersomnia Treatment Market Share by Country (2018-2029)
Figure 20. United States Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Idiopathic Hypersomnia Treatment Market Share by Country (2018-2029)
Figure 24. Germany Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Idiopathic Hypersomnia Treatment Market Share by Region (2018-2029)
Figure 32. China Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Idiopathic Hypersomnia Treatment Market Share by Country (2018-2029)
Figure 40. Mexico Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Idiopathic Hypersomnia Treatment Market Share by Country (2018-2029)
Figure 44. Turkey Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Takeda Pharmaceutical Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 47. Teva Pharmaceutical Industries Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 48. Jazz Pharmaceuticals Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 49. BIOPROJET Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 50. Avadel Pharmaceuticals Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 51. GlaxoSmithKline Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 52. Pfizer Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 53. Theranexus Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 54. Fisher and Paykel Healthcare Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 55. Drive DeVilbiss Healthcare Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 56. Merck Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
